Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is identified as one of the best fundamentally strong penny stocks to buy right now. Trexquant Investment LP reduced its stake in ADVM by 80.5% during the first quarter, offloading 77,303 shares and now holding 18,694 shares valued at approximately $82,000. The firm’s ownership is 0.09%.

In its recent financial results announcement, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) highlighted progress in the ARTEMIS Phase 3 trial, with enrollment driven by growing enthusiasm from retina specialists and patients. The company is ahead of schedule, sparking strategic partnership talks as momentum builds.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a clinical-stage company based in Redwood City, California, focusing on gene therapy product candidates for ocular diseases. The company’s management is actively engaged in ongoing partnering discussions and has received a vote of confidence from Frazier Life Sciences, one of its largest investors.

While ADVM shows investment potential, some AI stocks may offer greater upside potential with less downside risk. For those seeking an undervalued AI stock that could benefit from Trump-era tariffs and the onshoring trend, consider exploring the best short-term AI stock in a free report available.

Read more at Yahoo Finance: Trexquant Slashes Stake in Adverum Biotechnologies, Inc. (ADVM)